Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s mobile device integrated auto-injector platform, including ...
DETROIT & BOSTON, December 04, 2025--(BUSINESS WIRE)--Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s ...
A new mold concept developed by Zahoransky is engineered to accelerate the mass production of housings for insulin pens and auto injectors in a space- and energy-efficient manner. The Z.Sonic turn ...
Celltrion is offering Avtozma (tocilizumab-anoh) intravenous formulation, which is a biosimilar of Chugai Pharmaceutical’s Actemra. Avtozma is used to treat rheumatoid arthritis, giant cell arteritis, ...
If you or someone you love has an allergy that results in anaphylaxis, you know how important it is to administer epinephrine at the first sign of a reaction. Epinephrine is the frontline treatment ...
As part of the back-to-school rush, GoodRx, a platform for medication savings, reports the demand for epinephrine (EpiPen, EpiPen Jr, Adrenaclick, Auvi-Q) auto-injectors tends to spike in the summer ...
The recall affects certain models of the 2021-2024 Ford Bronco Sport and 2020-2022 Ford Escape, with 1.5L engines. Credit: Alexander Fedosov/Shutterstock.com. Ford Motor Company has announced a recall ...
Allergist talks about anaphylactic reactions to food and venom allergies and how important it is to choose the right epinephrine auto injector to suit peoples needs. Trump admin sending Taliban $45M ...
The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...
Organon acquired regulatory and commercial rights in the United States for TOFIDENCE ™, a biosimilar to ACTEMRA ®, for intravenous infusion from Biogen. TOFIDENCE, the first approved tocilizumab ...
Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar developed by Biogen (NASDAQ:BIIB) as an intravenous therapy targeting Roche’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback